查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1467955

RNA 治療市場：按技術、適應症和最終用戶分類 - 2024-2030 年全球預測

RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Indication (Cancer, Cardiovascular, Genetic Disorders), End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年RNA治療市場規模為21.8億美元，預計2024年將達26億美元，2030年將達89.8億美元，複合年成長率為22.38%。

RNA 療法涉及利用核糖核酸 (RNA) 分子靶向特定基因序列或細胞機制的治療方法的開發和商業化。這些治療方法透過靶向 RNA 分子來取代缺陷基因、抑制有害基因表現或調節細胞功能來治療多種疾病和病症。對生物技術新興企業的投資增加、學術界和工業界參與者之間不斷加強的合作以及針對未滿足的醫療需求不斷擴大的潛在治療標靶組合正在推動對 RNA 療法的需求。孤兒藥認定和加速核准等有利的監管政策加速了多種基於 RNA 的治療方法的臨床開發。與體內 RNA 分子的不穩定性和快速分解相關的遞送挑戰正在阻礙市場成長。製藥公司在利用最尖端科技對治療選擇有限的罕見疾病進行新型 RNA 療法方面不斷取得進展，預計將為市場成長創造機會。

主要市場統計
基準年[2023] 21.8億美元
預測年份 [2024] 26億美元
預測年份 [2030] 89.8億美元
複合年成長率（%） 22.38%

技術：對可用技術的需求不斷成長將推動 RNA 療法的進步。

透過提供精確操縱 RNA 分子並將其遞送至目標細胞所需的工具，可用技術將加速 RNA 治療的進步。該技術透過將小干擾 RNA (siRNA) 引入細胞來定序特定基因。實行技術透過提供改進的設計、合成、修飾和傳遞 RNA 分子的方法來促進實行技術的開發和應用。 RNA干擾(RNAi)、反義寡核苷酸 (ASO) 和信使核糖核酸 (mRNA) 療法等技術提供了根據目標疾病機制調節基因表現的不同方法。

適應症 RNA 療法在遺傳和癌症疾病方面的廣泛應用。

RNA療法透過針對特定的癌基因和抑癌基因，在癌症治療中極為重要。這些治療方法有助於控制癌細胞中經常被破壞的基因表現。基於需求的癌症 RNA 治療偏好包括根據患者基因組成量身定做的個人化治療。 RNA療法透過調節疾病相關基因的表達，在治療心臟衰竭和高血壓等心血管疾病方面具有潛在的應用。患有嚴重或罕見心血管疾病的患者可能會受益於這種標靶治療，因為它們比傳統治療方法副作用更少且更有效。 RNA療法可用於治療單一基因突變或缺陷引起的遺傳性疾病。這種基於需求的優先重點是針對患有罕見且危及生命的遺傳性疾病且治療選擇有限的患者。 RNA 療法可以透過調節宿主的免疫反應或直接針對病原體來對抗病毒和細菌感染，例如 COVID-19、B型肝炎和結核病。優先考慮抗藥性感染疾病患者和感染疾病期間需要快速反應的患者。 RNA療法透過針對參與腎功能和纖維化的特定基因，為多囊性腎病變和糖尿病腎臟病等慢性腎臟病提供了新的治療選擇。 RNA療法有潛力透過調節參與葡萄糖和脂質代謝的關鍵基因來治療肥胖、非酒精性脂肪性肝炎(NASH)和第2型糖尿病等代謝性疾病。除了癌症疫苗之外，RNA療法還用於透過編碼患者特異性腫瘤抗原來開發針對各種腫瘤類型的個人化免疫療法。這種基於需求的偏好針對的是對標準治療方法反應不佳的侵襲性或轉移性癌症患者。 RNA療法可以透過將受影響基因的功能副本直接傳遞到視網膜細胞中來幫助治療由基因突變引起的視網膜疾病，例如萊伯氏先天性黑朦症和老齡化黃斑部病變。

最終用戶：學術研究越來越重視推動診斷和藥物開發的新發現。

學術研究主要使用RNA療法來了解基因功能和調控。研究人員採用了多種 RNA 治療方法，包括小干擾 RNA (siRNA)、反義寡核苷酸 (ASO)、微型RNA(miRNA) 和傳訊RNA(mRNA) 療法。基於 RNA 的診斷著重於透過標靶序列測定和基因表現檢測疾病特異性生物標記。與傳統的基於 DNA 的方法相比，這些診斷方法提高了靈敏度。 RNA 標靶藥物的發現和開發涉及識別新的治療標靶、設計選擇性 RNA 結合小分子或寡核苷酸以及開發創新的遞送系統來克服細胞損傷。

區域洞察

美洲 RNA 治療市場得到發達的醫療保健部門和政府支持計劃的支持，美國和加拿大的尖端 RNA 療法已實現顯著商業化，南美國家的製藥業正在發展。美洲各國政府鼓勵技術進步和研究工作，以為人民提供更好的醫療保健系統，並為整體經濟成長和公共福祉做出貢獻。日本、印度、中國和韓國等亞太地區新興經濟體和已開發經濟體的政府正在鼓勵 RNA 療法的研究和開發。隨著新設備和技術迅速商業化並被接受，RNA 療法在歐洲已廣泛採用，醫療保健專業人員也能使用 RNA 療法。同時，歐洲人口老化正在迅速加劇，多種感染疾病和慢性病的適應症預計將增加。根據人口研究所（PRB）的數據，俄羅斯、德國、義大利、法國、英國、西班牙、土耳其、烏克蘭、波蘭、奈及利亞和伊朗是65歲及以上人口比例最高的國家。由於歐洲人口老化和殘疾徵兆像日益增多，需要有效的 RNA 療法。

FPNV定位矩陣

FPNV定位矩陣對於評估RNA治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對 RNA 治療市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.RNA治療市場的市場規模與預測是多少？

2.RNA治療市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.RNA治療市場的技術趨勢和法規結構是什麼？

4.RNA治療市場主要廠商的市場佔有率為何？

5.進入RNA治療市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 加深我們對 RNA 在疾病病理學中作用的理解
      • 個人化醫療需求不斷成長
      • 透過與製藥公司的策略聯盟促進新藥開發
    • 抑制因素
      • RNA 療法開發過程相關的高成本
    • 機會
      • 政府和私人組織增加對研發活動的投資
      • 基於 RNA 的療法的臨床試驗管道
    • 任務
      • RNA分子的不穩定性和嚴格的監管指南引起的問題
  • 市場區隔分析
    • 技術：對推動 RNA 治療進步的技術的需求不斷成長。
    • 適應症：RNA療法在遺傳和癌症疾病的廣泛應用。
    • 最終用戶：專注於推動診斷和藥物開發的新發現的學術研究變得越來越重要。
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章 RNA 治療市場：依技術分類

  • 使能技術
  • 實行技術

第7章 RNA 治療市場（按適應症）

  • 癌症
  • 心血管
  • 遺傳疾病
  • 感染疾病
  • 腎臟疾病
  • 代謝紊亂
  • 腫瘤學
  • 視網膜疾病

第8章 RNA 治療市場：依最終使用者分類

  • 學術研究
  • 診斷
  • 藥物發現與開發

第9章美洲RNA治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太RNA治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的RNA治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 下一代 RNA 療法的領導者 ADARx Pharmaceuticals 宣布超額認購 2 億美元 C 輪資金籌措
    • ReNAgade Therapeutics 斥資 3 億美元進軍 RNA 治療領域
    • Esperovac 和 Gingo Bioworks 宣布合作開發基於環狀 RNA 的療法

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-0375F3EAA7E7

[187 Pages Report] The RNA Therapy Market size was estimated at USD 2.18 billion in 2023 and expected to reach USD 2.60 billion in 2024, at a CAGR 22.38% to reach USD 8.98 billion by 2030.

RNA therapy includes developing and commercializing therapeutic approaches that utilize ribonucleic acid (RNA) molecules to target specific genetic sequences and cellular mechanisms. These therapies treat various diseases and conditions by replacing faulty genes, silencing harmful gene expressions, or modulating cellular functions by targeting RNA molecules. Increasing investments in biotechnology startups, growing collaborations between academia and industry players, and an expanding portfolio of potential therapeutic targets for unmet medical needs drive the need for RNA therapies. Favorable regulatory policies for orphan drug designation and fast-track approvals have accelerated the clinical development of several RNA-based therapies. Delivery challenges associated with instability and rapid degradation of RNA molecules in vivo hampers market growth. Ongoing advancements by pharmaceutical companies to leverage cutting-edge technologies into novel RNA treatments for rare diseases with limited treatment options are expected to create opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 2.18 billion
Estimated Year [2024] USD 2.60 billion
Forecast Year [2030] USD 8.98 billion
CAGR (%) 22.38%

Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.

Enabled technology drives the advancement in RNA therapy as it provides the tools necessary for precisely manipulating and delivering RNA molecules to target cells. This technology silences specific genes by introducing small interfering RNAs (siRNAs) into cells. Enabling technologies facilitate the development and application of enabled technologies by providing improved RNA molecule design, synthesis, modification, and delivery methods. Enabled technologies such as RNA interference (RNAi), Antisense Oligonucleotides (ASOs), and messenger Ribonucleic Acid (mRNA) therapeutics offer different approaches to modulating gene expression depending on the targeted disease mechanism.

Indication: Widespread applications of RNA therapy in genetic and cancer diseases.

RNA therapy is crucial in cancer treatment by targeting specific oncogenes or tumor suppressor genes. These therapies help to regulate gene expression, which is often disrupted in cancerous cells. Need-based preference for RNA therapy in cancer includes personalized treatments tailored to the patient's genetic makeup. RNA therapy has potential applications for treating cardiovascular diseases such as heart failure and hypertension by modulating the expression of disease-related genes. Patients with severe or rare cardiovascular conditions may benefit from these targeted therapies as they offer fewer side effects and better efficacy compared to conventional treatments. RNA therapy can be used to treat genetic disorders caused by mutations or deficiencies in single genes. This need-based preference focuses on patients with rare, life-threatening genetic diseases with limited treatment options. By modulating host immune responses or directly targeting pathogens, RNA therapy can help combat viral and bacterial infections such as COVID-19, hepatitis B, and tuberculosis. Preference exists for patients suffering from drug-resistant infections or requiring rapid response treatments during outbreaks. RNA therapy provides new treatment options for chronic kidney diseases such as polycystic kidney disease and diabetic nephropathy by targeting specific genes involved in renal function and fibrosis. RNA therapy has the potential to treat metabolic disorders, including obesity, non-alcoholic steatohepatitis (NASH), and type 2 diabetes by regulating key genes involved in glucose and lipid metabolism. In addition to cancer vaccines, RNA therapy is used to develop personalized immunotherapies for various tumor types by encoding patient-specific tumor antigens. This need-based preference targets patients with aggressive or metastatic cancers that do not respond well to standard treatments. RNA therapy helps to treat retinal diseases caused by genetic mutations, such as Leber's congenital amaurosis and age-related macular degeneration, by delivering functional copies of the affected genes directly into retinal cells.

End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.

In academic research, RNA therapy is primarily utilized for understanding gene function and regulation. Researchers employ various RNA therapeutic approaches such as small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), microRNAs (miRNAs), and messenger RNA (mRNA) therapeutics. RNA-based diagnostics focuses on detecting disease-specific biomarkers through targeted sequencing or gene expression profiling. These diagnostic methods offer increased sensitivity compared to traditional DNA-based techniques. RNA-targeted drug discovery and development involve identifying novel therapeutic targets, designing selective RNA-binding small molecules or oligonucleotides, and developing innovative delivery systems to overcome cellular barriers.

Regional Insights

The RNA therapy market in the Americas is supported by a developed healthcare sector and supportive government programs, resulting in considerable commercialization of cutting-edge RNA therapies in the United States and Canada and the evolving pharmaceutical industry in South American countries. The governments in the Americas encourage technological advancements and research activities to provide a better healthcare system to people that contribute to overall economic growth and public welfare. The governments in the Asia-Pacific region's emerging and developed economies, such as Japan, India, China, and South Korea, encourage research and development of RNA therapies. Europe has significantly adopted RNA therapies owing to the rapid commercialization and acceptability of new devices and technologies, enabling healthcare professionals to use RNA therapies. On the other hand, the surging geriatric population in Europe is expected to increase the indication of several infectious and chronic disorders. As per the Population Reference Bureau (PRB), Russia, Germany, Italy, France, the UK, Spain, Turkey, Ukraine, Poland, Nigeria, and Iran are some countries that have a significant percentage of the population aged over 65 years. The rising indication of Europe's aging population and disorders necessitates efficient RNA therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the RNA Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the RNA Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Deep Genomics, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Ionis Pharmaceuticals, Inc., Laronde, MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, Novartis AG, Novo Nordisk A/S, Nutcracker Therapeutics, Inc., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Triplet Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Enabled Technologies
      • Inhibition
      • Labeling
      • Linear amplification
      • Microarrays
      • Purification
      • qRT-PCR
    • Enabling Technologies
      • RNA Antisense Technologies
        • MicroRNA
        • Small interfering RNA
      • RNA Interference Technologies
  • Indication
    • Cancer
    • Cardiovascular
    • Genetic Disorders
    • Infectious Diseases
    • Kidney Diseases
    • Metabolic Disorders
    • Oncology
    • Retinal Diseases
  • End User
    • Academic Research
    • Diagnostics
    • Drug Discovery & Development
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the RNA Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the RNA Therapy Market?

3. What are the technology trends and regulatory frameworks in the RNA Therapy Market?

4. What is the market share of the leading vendors in the RNA Therapy Market?

5. Which modes and strategic moves are suitable for entering the RNA Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing understanding of the role of RNA in disease pathology
      • 5.1.1.2. Heightened demand for personalized medicine
      • 5.1.1.3. Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with RNA therapy development processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased investments by governments and private organizations in research and development activities
      • 5.1.3.2. Pipelined clinical trials of RNA-based therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
    • 5.2.2. Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
    • 5.2.3. End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis
  • 5.8. Client Customization

6. RNA Therapy Market, by Technology

  • 6.1. Introduction
  • 6.2. Enabled Technologies
  • 6.3. Enabling Technologies

7. RNA Therapy Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cardiovascular
  • 7.4. Genetic Disorders
  • 7.5. Infectious Diseases
  • 7.6. Kidney Diseases
  • 7.7. Metabolic Disorders
  • 7.8. Oncology
  • 7.9. Retinal Diseases

8. RNA Therapy Market, by End User

  • 8.1. Introduction
  • 8.2. Academic Research
  • 8.3. Diagnostics
  • 8.4. Drug Discovery & Development

9. Americas RNA Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific RNA Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa RNA Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
    • 12.3.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
    • 12.3.3. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. RNA THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. RNA THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RNA THERAPY MARKET DYNAMICS
  • FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 313. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 314. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 325. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 326. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 336. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 337. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 338. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 343. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 344. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 345. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 346. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 347. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 348. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 349. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 350. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 354. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 355. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 356. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 357. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 358. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 359. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 360. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 361. GERMANY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 362. GERMANY RNA THERAPY MARKET SIZE, BY TE